12 Sep 20171 Dec 2017Biotechnology.Jonathan Aschoff.Research

Mustang Bio, Inc. (MBIO)

Mustang Bio, Inc. | BUY (MBIO, $12.03) | Focused on Effective CAR T Therapies that Address Earlier Generation CAR T Safety Concerns: Initiating BUY/$21 TP

29 Aug 20171 Dec 2017Business Development Companies.Christopher Testa.Research

Saratoga Investment Corp. (SAR)

Saratoga Investment Corp. | NEUTRAL ( SAR, $21.26) | Lower Middle Market Focused BDC with Ample Dry Powder to Drive Strong Portfolio Growth with Minimal Equity Issuance, Significant Non-Sponsor and Second Lien Composition Keep Us On the Sidelines For Now - Initiating With a NEUTRAL Rating And $23 Price Target.

28 Aug 20171 Dec 2017Ilya Grozovsky.Research.Technology

Digimarc Corporation (DMRC)

Digimarc Corporation | BUY (DMRC, $28.35) | Retail Revolution Driven By The Barcode – Initiating With A BUY Rating & $36 PT

15 Aug 20171 Dec 2017Biotechnology.Jonathan Aschoff.Research

Avenue Therapeutics, Inc. (ATXI)

Avenue Therapeutics, Inc. | BUY (ATXI, $6.77) | IV Tramadol for Post-Operative Pain - Derisked Late Stage Development Combined with Low Abuse Potential, a Strong Positive Given the Current Opioid Epidemic: Initiating BUY/$15 TP

1 Jul 20171 Dec 2017John Benda.REITS.Research

Terreno Realty Corporation, Inc. (TRNO)

Terreno Realty Corporation, Inc. | BUY ( TRNO, $20.12) | Lowest Risk Operator with Best Asset Base - Initiating With a BUY Rating and $23.50 Price Target